EP Patent

EP2632467A1 — Cdk inhibitors

Assigned to G1 Therapeutics Inc · Expires 2013-09-04 · 13y expired

What this patent protects

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

USPTO Abstract

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Drugs covered by this patent

Patent Metadata

Patent number
EP2632467A1
Jurisdiction
EP
Classification
—
Expires
2013-09-04
Drug substance claim
No
Drug product claim
No
Assignee
G1 Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.